We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

63 hedge funds and large institutions have $36.7M invested in Palvella Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

319% more call options, than puts

Call options by funds: $88K | Put options by funds: $21K

0.01% more ownership

Funds ownership: 0.59% → 0.59% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 65 → 63 (-2)

9% less capital invested

Capital invested by funds: $40.1M → $36.7M (-$3.41M)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

Holders
63
Holders Change
-2
Holders Change %
-3.08%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
13
Reduced
21
Closed
9
Calls
$88K
Puts
$21K
Net Calls
+$67K
Net Calls Change
-$41K

Top Buyers

1
Bank of America
Bank of America
North Carolina
+$3.15M
2
LCM
Lynx1 Capital Management
Puerto Rico
+$2.12M
3
ACM
Aquilo Capital Management
California
+$519K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$484K
5
Millennium Management
Millennium Management
New York
+$402K

Top Sellers

1
SCM
Soleus Capital Management
Connecticut
-$3.15M
2
GPP
Great Point Partners
Connecticut
-$2.26M
3
Morgan Stanley
Morgan Stanley
New York
-$943K
4
CS
Candriam SCA
Luxembourg
-$121K
5
Cerity Partners
Cerity Partners
New York
-$110K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynx1 Capital Management
Puerto Rico
$5.85M +$2.12M +26,418 +60%
BI
2
BVF Inc
California
$5.28M – – –
ACM
3
Aquilo Capital Management
California
$4.73M +$519K +6,457 +13%
Bank of America
4
Bank of America
North Carolina
$3.81M +$3.15M +39,173 +589%
Marshall Wace
5
Marshall Wace
United Kingdom
$2.49M -$49.4K -615 -2%
Citadel Advisors
6
Citadel Advisors
Florida
$2.13M +$5.14K +64 +0.3%
BlackRock
7
BlackRock
New York
$1.38M +$1.13K +14 +0.1%
PIM
8
Platinum Investment Management
Australia
$1.27M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.11M +$1.45K +18 +0.1%
SCM
10
Soleus Capital Management
Connecticut
$1.04M -$3.15M -39,186 -76%
CS
11
Candriam SCA
Luxembourg
$979K -$121K -1,500 -11%
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$916K +$121K +1,507 +16%
Renaissance Technologies
13
Renaissance Technologies
New York
$714K -$44.4K -552 -6%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$655K -$1.45K -18 -0.2%
Millennium Management
15
Millennium Management
New York
$577K +$402K +5,006 +259%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$501K +$484K +6,022 New
CCB
17
Cutter & Co Brokerage
Missouri
$394K -$28.2K -351 -7%
GCP
18
GSA Capital Partners
United Kingdom
$380K +$367K +4,563 New
SPC
19
Sigma Planning Corp
Michigan
$358K +$28.4K +354 +9%
Jacobs Levy Equity Management
20
Jacobs Levy Equity Management
New Jersey
$337K -$69.3K -863 -18%
Morgan Stanley
21
Morgan Stanley
New York
$227K -$943K -11,731 -81%
State Street
22
State Street
Massachusetts
$218K – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
$138K +$7.23K +90 +6%
BCM
24
Bridgeway Capital Management
Texas
$121K – – –
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$118K -$20.7K -258 -15%
1
2 3

PVLA Hedge Fund Activity: Q4 2022 in Review

63 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2022, worth a combined $36.7M — down 8.5% from $40.1M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PVLA and 7 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.

The largest buyer was Bank of America, adding an estimated $3.15M. The largest seller was Soleus Capital Management, cutting an estimated $3.15M.

  • 63 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2022, down from 65 in Q3 2022.
  • Funds reported $36.7M of Palvella Therapeutics stock for Q4 2022, down 8.5% quarter-over-quarter.
  • 7 funds opened new Palvella Therapeutics positions in Q4 2022 and 9 closed out, a net change of -2 holders.
  • The largest Palvella Therapeutics buyer in Q4 2022 was Bank of America, an estimated $3.15M added.
  • The largest Palvella Therapeutics seller in Q4 2022 was Soleus Capital Management, an estimated $3.15M sold.

Based on aggregated 13F filings for Q4 2022.